Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

1.

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).

J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.

PMID:
15231010
[PubMed - indexed for MEDLINE]
2.

Beyond daily dosing: clinical experience.

Cooper C.

Bone. 2006 Apr;38(4 Suppl 1):S13-7. Epub 2006 Mar 7. Review.

PMID:
16520105
[PubMed - indexed for MEDLINE]
3.

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

Epstein S, Jeglitsch M, McCloskey E.

Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Review.

PMID:
19835464
[PubMed - indexed for MEDLINE]
4.

Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.

Reginster JY.

Curr Pharm Des. 2005;11(28):3711-28. Review.

PMID:
16305506
[PubMed - indexed for MEDLINE]
5.
6.

Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.

Rossini M, Viapiana O, Gatti D, Adami S.

Clin Ther. 2009 Jul;31(7):1497-510. doi: 10.1016/j.clinthera.2009.07.018. Review.

PMID:
19695399
[PubMed - indexed for MEDLINE]
7.

Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.

Pyon EY.

Clin Ther. 2006 Apr;28(4):475-90. Review.

PMID:
16750461
[PubMed - indexed for MEDLINE]
8.

Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.

Miller PD.

Clin Ther. 2005 Apr;27(4):361-76. Review.

PMID:
15922811
[PubMed - indexed for MEDLINE]
9.

Once-monthly dosing: an effective step forward.

Reid DM.

Bone. 2006 Apr;38(4 Suppl 1):S18-22. Epub 2006 Mar 13. Review.

PMID:
16533625
[PubMed - indexed for MEDLINE]
10.

Strontium ranelate: a new paradigm in the treatment of osteoporosis.

Reginster JY, Deroisy R, Jupsin I.

Drugs Today (Barc). 2003 Feb;39(2):89-101. Review.

PMID:
12698204
[PubMed - indexed for MEDLINE]
11.

Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.

Sebba AI.

Clin Ther. 2008 Mar;30(3):443-52. doi: 10.1016/j.clinthera.2008.03.008. Review. Erratum in: Clin Ther. 2008 Jun;30(6):1177-8.

PMID:
18405784
[PubMed - indexed for MEDLINE]
12.

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.

Reginster JY, Felsenberg D, Cooper C, Stakkestad JA, Miller PD, Kendler DL, Adami S, McClung MR, Bolognese MA, Civitelli R, Dumont E, Bonvoisin B, Recker RR, Delmas PD.

Osteoporos Int. 2006 Feb;17(2):159-66. Epub 2005 Jun 14. Review.

PMID:
15959614
[PubMed - indexed for MEDLINE]
13.

Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy.

Amling M, Kurth A.

Womens Health (Lond Engl). 2009 Sep;5(5):467-73. doi: 10.2217/whe.09.38. Review.

PMID:
19702445
[PubMed - indexed for MEDLINE]
14.

Bisphosphonates for prevention of postmenopausal osteoporosis.

Ravn P.

Dan Med Bull. 2002 Feb;49(1):1-18. Review.

PMID:
11894721
[PubMed - indexed for MEDLINE]
15.

Once-monthly ibandronate.

Dando TM, Noble S.

Treat Endocrinol. 2005;4(6):381-7; discussion 389-90. Review.

PMID:
16318406
[PubMed - indexed for MEDLINE]
16.

Aging bone and osteoporosis: strategies for preventing fractures in the elderly.

Ettinger MP.

Arch Intern Med. 2003 Oct 13;163(18):2237-46. Review.

PMID:
14557222
[PubMed - indexed for MEDLINE]
17.

Strontium ranelate in osteoporosis.

Reginster JY.

Curr Pharm Des. 2002;8(21):1907-16. Review.

PMID:
12171530
[PubMed - indexed for MEDLINE]
18.

[Update on treatment of postmenopausal osteoporosis].

Body JJ.

Rev Med Brux. 2008 Sep;29(4):301-9. Review. French.

PMID:
18949981
[PubMed - indexed for MEDLINE]
19.

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

Bauss F, Russell RG.

Osteoporos Int. 2004 Jun;15(6):423-33. Epub 2004 Mar 26. Review.

PMID:
15205712
[PubMed - indexed for MEDLINE]
20.

Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data.

Miller PD.

Curr Med Res Opin. 2008 Jan;24(1):107-19. Review.

PMID:
18031594
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk